Zeo ScientifiX, Inc. SEC Filings

Amendment No. 2 to a Schedule 13D reports that Wendy Grey and Greyt Ventures, LLC are major holders of Zeo Scientifix, Inc. equity. They beneficially own 2,117,500 shares of common stock, including 1,155,000 shares issuable upon exercise of warrants, 87,500 restricted shares vesting on July 14, 2026, and 625,000 shares issuable upon exercise of options.

This position represents 23.88% of the common stock class, based on 7,837,441 shares outstanding as of June 12, 2026 and giving effect to the warrants and options. The reporting person also holds 50 shares of Series C Preferred Stock, providing an additional 25.5% of total voting power, for aggregate voting power of 49.38%. The reporting person has sole voting and dispositive power over all 2,117,500 common shares.

The additional interests disclosed arise from equity compensation: restricted stock issued on January 14, 2026 and options granted on June 10, 2026 under the issuer’s 2021 Equity Incentive Plan. The reporting person states no current plans for acquisitions, dispositions, or corporate actions beyond ordinary-course possibilities and potential future equity awards.

Zeo Scientifix, Inc. insider Ian T. Bothwell filed an amendment updating his ownership in the company’s common and Series C preferred stock. He beneficially owns 1,820,094 common shares, representing 20.6% of the common stock after giving effect to his warrants and options, based on 7,837,441 shares outstanding as of June 12, 2026.

His holdings include restricted stock, warrants and options, including a new grant of options for 625,000 shares on June 10, 2026 under the 2021 Equity Incentive Plan. Bothwell also holds 50 Series C Preferred shares that provide an additional 25.5% of total voting power, giving him aggregate voting power of 46.1%. He reports sole voting and dispositive power over his common shares and states he has no definite plans for significant acquisitions, dispositions or corporate control changes.

George Shapiro, M.D. filed Amendment No. 1 to a Schedule 13G reporting his beneficial ownership in Zeo Scientifix, Inc. common stock. He reports beneficially owning 1,311,271 shares of common stock, representing 15.1% of the class. These percentages are based on 7,837,441 shares outstanding as of June 12, 2026, as reported by the company. Shapiro has sole voting and sole dispositive power over all 1,311,271 shares, with no shared voting or dispositive power.

ZEO ScientifiX, Inc. describes new efforts to strengthen its role within South Florida’s healthcare innovation ecosystem. On July 21, 2026, the company highlighted regenerative biologic research and development, physician education, and scientific collaboration as core focus areas, operating from Nova Southeastern University’s Center for Collaborative Research in Davie, Florida.

The company is expanding physician Master Classes, webinars, scientific programming, professional collaborations, and its Medical Advisory Board to connect emerging regenerative medicine science with clinical practice. ZEO ScientifiX presents these initiatives as supporting meaningful scientific exchange and the responsible advancement of regenerative medicine from a South Florida base.

ZEO ScientifiX, Inc. reported very strong growth for the quarter and six months ended April 30, 2026, highlighted in a press release tied to its latest Form 10-Q. Quarterly revenue reached $2.58 million, up 124.6% from $1.15 million a year earlier, driven mainly by higher sales of allogenic biologic products.

For the six-month period, revenue was $4.03 million, an increase of 79.9% from $2.24 million in the prior year period. The company maintained gross margins of about 80% in both 2026 and 2025 six-month periods while reducing its net loss to roughly $1.0 million from about $2.6 million a year earlier. Management attributes this to accelerating commercial momentum, growing physician adoption, and rising demand for its regenerative biologics portfolio.

ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational initiative for healthcare professionals. The company will host a live virtual webinar titled “One Year Later, Three States Stronger: The Southeast Regen Revolution” on July 22, 2026, at 6:45 p.m. Eastern Time.

The program will review Florida’s first year under its pioneering stem cell law and discuss similar laws recently adopted in Tennessee and Georgia. Led by General Manager Sean Vega-Stanton, M.D., the expert panel will cover scientific, medical, and regulatory perspectives in regenerative medicine.

ZEO ScientifiX, Inc. filed a report describing a humanitarian initiative supported by the company. Medical Advisory Board member Dr. Constantino Mendieta joined a 10-day pediatric burn reconstruction mission in Cusco, Peru, where he used products that had been donated to him by ZEO ScientifiX.

During the mission, approximately 80 children were evaluated and nearly 40 reconstructive surgeries were performed over six days at the Regional Hospital of Cusco. ZEO frames this product donation as part of a broader commitment to physician-led care, regenerative medicine education, and expanding access to advanced therapeutic options for patients in need.

Zeo ScientifiX, Inc. reported sharply higher sales but remains unprofitable and faces substantial doubt about its ability to continue as a going concern. Revenue for the three months ended April 30, 2026 rose to $2.58 million from $1.15 million, driven mainly by allogenic biologic products in Florida’s evolving stem cell market. Six‑month revenue reached $4.03 million, with gross margins around 80%.

The company still posted a net loss of $145,000 for the quarter and $997,000 for the six months, though losses narrowed versus the prior year. Operating cash outflow was $609,000 over six months, offset by $1.95 million of equity financing and $376,000 from selling its Exotropin stake, lifting cash to $1.85 million. At April 30, 2026, stockholders’ equity improved to $712,000 and working capital to $155,000, yet management and auditors still highlight regulatory risk around FDA stem‑cell rules, reliance on new state laws such as Florida SB 1768, and the need for additional funding to support clinical trials and growth.

Zeo ScientifiX, Inc. reported stock option awards to a major holder and related entity. The filing shows grants of options under the company’s 2021 Equity Incentive Plan, exercisable at an exercise price of $1.67 per share and expiring on June 10, 2036.

Footnotes explain that the options were issued to Greyt Ventures, LLC, a principal stockholder and consultant owned by a trust for which Wendy Grey is trustee. One grant vests upon achieving performance milestones, while another vested in full at the grant date, and both are exercisable on a cashless basis with anti-dilutive features tied to large future issuances.